FOLH1 and prostate carcinoma: Although targeting ligands such as those against prostate-specific membrane antigen (PSMA) are commonly used in prostate cancer nanomedicine, specific applications involving PSMA-targeted melittin-based nanotherapy were not identified in recent studies.